Compare PLSE & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ENOV |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2015 | 2008 |
| Metric | PLSE | ENOV |
|---|---|---|
| Price | $25.30 | $25.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $22.00 | ★ $47.38 |
| AVG Volume (30 Days) | 326.9K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | $6.36 |
| Revenue Next Year | $287.54 | $5.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $21.00 |
| 52 Week High | $27.98 | $36.82 |
| Indicator | PLSE | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 52.88 |
| Support Level | $17.58 | $21.52 |
| Resistance Level | $26.30 | $27.11 |
| Average True Range (ATR) | 1.72 | 1.43 |
| MACD | 0.59 | 0.03 |
| Stochastic Oscillator | 74.53 | 54.60 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.